Pyxis Oncology FY2030 EPS Estimate Reduced by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Research analysts at HC Wainwright lowered their FY2030 earnings per share (EPS) estimates for shares of Pyxis Oncology in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.76 for the year, down from their prior forecast of $0.77. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.22) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).

Several other research analysts have also weighed in on PYXS. Wedbush began coverage on shares of Pyxis Oncology in a report on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective for the company. Leerink Partners reduced their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, July 2nd. Weiss Ratings downgraded Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company initiated coverage on Pyxis Oncology in a research note on Monday, August 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.50.

Pyxis Oncology Trading Down 1.0%

PYXS stock opened at $2.99 on Wednesday. The firm has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $1.99. The company has a market capitalization of $189.43 million, a P/E ratio of -2.12 and a beta of 1.31. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55.

Institutional Trading of Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Renaissance Technologies LLC boosted its holdings in shares of Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after buying an additional 160,300 shares during the period. J. Derek Lewis & Associates Inc. bought a new position in Pyxis Oncology in the fourth quarter worth about $61,000. XTX Topco Ltd boosted its stake in Pyxis Oncology by 1,533.0% in the fourth quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock valued at $332,000 after acquiring an additional 271,334 shares during the period. Toronto Dominion Bank bought a new position in shares of Pyxis Oncology during the fourth quarter valued at approximately $86,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Pyxis Oncology during the 4th quarter worth approximately $116,000. 39.07% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.